Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Zosano Pharma Corporation (NASDAQ:ZSAN) announced that its CEO, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am ET. A webcast will be available on the company’s website, remaining accessible for 90 days post-event.

The company focuses on developing products for rapid administration of known molecules, addressing patient needs with its proprietary transdermal microneedle technology. Its lead product candidate, Qtrypta™ (M207), targets acute migraine treatment.

FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference that will be available on Monday, January 11, 2021 at 6:00 am ET.

A webcast of the presentation can be accessed on the company’s website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 90 days following the date of the event.

About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.

Zosano Contact:
Christine Matthews
Chief Financial Officer
510-745-1200

PR Contacts:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com

FAQ

What is the date and time of Zosano Pharma's presentation at the H.C. Wainwright Conference?

Zosano Pharma's CEO will present on January 11, 2021, at 6:00 am ET.

Where can I access the webcast for Zosano Pharma's presentation?

The webcast can be accessed on Zosano Pharma’s website at http://ir.zosanopharma.com/events-presentations.

What is Zosano Pharma's lead product candidate?

Zosano Pharma's lead product candidate is Qtrypta™ (M207), designed for acute migraine treatment.

What technology does Zosano Pharma use in its product development?

Zosano Pharma uses a transdermal microneedle system technology for rapid systemic drug administration.

How long will the archived webcast of Zosano Pharma's presentation be available?

The archived webcast will be available for 90 days following the event.